Northwestern Neuromuscular Disease Biorepository
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT07477509
- Status
- Recruiting
Conditions
- Neuromuscular Diseases (NMD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The primary objective of this research is to collect clinical data and tissue samples from adult patients with neuromuscular disease cared for at the Northwestern Memorial Hospital neuromuscular clinic (Lavin Building, 19th floor). This study has the following aims: Aim 1: To consent a large cohort of adult study participants with neuromuscular disorders, including but not limited to motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies for participation in the biorepository and to collect longitudinal data on their clinical disease phenotypes. Aim 2: To obtain and store biological samples from biorepository study participants, including whole blood, plasma, serum, peripheral blood mononuclear cells \[PBMCs\], skin biopsies, and cerebrospinal fluid. Aim 3: To develop a data-sharing process to provide de-identified biorepository participant clinical data and samples to partnered investigators to expedite discovery in neuromuscular disease diagnosis and treatment.
Key Dates
- Start date
- May 1, 2026
- Status verified
- May 2026
- Primary completion
- Mar 31, 2050
- Completion
- Mar 31, 2050
Study Design
- Enrollment
- 2,500 participants (estimated)
Primary Outcome Measure
Biospecimen Samples [ Time Frame: 50 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northwestern University Department of Neurology | Chicago | Illinois | 60611 | 6108062029 Ryan Donaghy, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Chicago, IL
Related Studies
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseRecruiting · University of Missouri-Columbia · Columbia, Missouri
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)PHASE3 · Recruiting · Dyne Therapeutics · Hillsborough, North Carolina